Lim Jong-yoon, CEO of Hanmi Science, Appointed Director of Cancerorp UK Subsidiary

Lim Jong-yoon, CEO of Hanmi Science / Photo by Moon Ho-nam munonam@

[Asia Economy Reporter Chunhee Lee] Cancerop, a molecular diagnostics specialist company, announced on the 25th that it has appointed Lim Jong-yoon, CEO of Hanmi Science, the largest shareholder, as a registered director of its British subsidiary, biopharmaceutical company Oxford Vacmedix.

Oxford Vacmedix is a bio-pharmaceutical company specializing in the development of anticancer immunovaccines located in Oxford Science Park, UK. It was established in 2012 as a spin-off from the University of Oxford. In 2018, Cancerop secured a 42.89% stake in the company, becoming the largest shareholder.

William Finch, CEO of Oxford Vacmedix, said, "We are pleased to have CEO Lim Jong-yoon join our board," adding that Lim will "play a role in collaborating and supporting the achievement of the vision to address unmet medical needs of cancer patients and the advancement of vaccine development research for post-pandemic infectious disease response."

CEO Lim Jong-yoon is the eldest son of the late Lim Sung-gi, former chairman of Hanmi Pharmaceutical Group. He majored in biochemistry at Boston University in the United States, served as president of Hanmi Pharmaceutical in 2009, and has been CEO of Hanmi Science, the holding company of Hanmi Group, since 2016. In August, he became the largest shareholder of Cancerop through a third-party allotment capital increase.

CEO Lim said, "We hope that Oxford Vacmedix's technology will provide safe and effective treatments so that cancer patients can live longer and better lives."